2006
DOI: 10.1016/j.ccr.2006.10.006
|View full text |Cite
|
Sign up to set email alerts
|

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Abstract: BCL-2 proteins are critical for cell survival and are overexpressed in many tumors. ABT-737 is a small-molecule BH3 mimetic that exhibits single-agent activity against lymphoma and small-cell lung cancer in preclinical studies. We here report that ABT-737 effectively kills acute myeloid leukemia blast, progenitor, and stem cells without affecting normal hematopoietic cells. ABT-737 induced the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathwa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

41
909
7

Year Published

2007
2007
2022
2022

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 912 publications
(957 citation statements)
references
References 57 publications
41
909
7
Order By: Relevance
“…Thus, the effects of Gfi-1 could be mimicked by inhibition of STAT 5 and Mcl-1 expression and/or activity. Pharmacological inhibition of Mcl-1 and STAT 5 activity suppresses proliferation and colony formation of p210BCR/ABL expressing cells In contrast to ABT-737 which antagonizes Bcl-2 and BCL-XL, 30,31 Obatoclax is a pan-Bcl-2 inhibitor which also blocks the activity of Mcl-1. 32,33 Thus, we treated K562 cells with Obatoclax (500 nM) and assessed their proliferation and colony formation.…”
Section: Resultsmentioning
confidence: 99%
“…Thus, the effects of Gfi-1 could be mimicked by inhibition of STAT 5 and Mcl-1 expression and/or activity. Pharmacological inhibition of Mcl-1 and STAT 5 activity suppresses proliferation and colony formation of p210BCR/ABL expressing cells In contrast to ABT-737 which antagonizes Bcl-2 and BCL-XL, 30,31 Obatoclax is a pan-Bcl-2 inhibitor which also blocks the activity of Mcl-1. 32,33 Thus, we treated K562 cells with Obatoclax (500 nM) and assessed their proliferation and colony formation.…”
Section: Resultsmentioning
confidence: 99%
“…The drugs tested included 17-allylaminogeldanamycin (17-AAG), a heat shock protein (HSP)-90 inhibitor and PS-341, a proteasome inhibitor; both have previously been shown to elevate Bim, Bad, Bmf or Bik expression. [15][16][17][18] We also examined whether the killing of INNO-406 could be enhanced by co-treatment with ABT-737, a drug that decreases the antiapoptotic barrier imposed by the antiapoptotic Bcl-2 family members Bcl-2, Bcl-X L and Bcl-w. 19,20 Our study shows that simultaneously targeting both pro-and antiapoptotic molecules augments the killing achieved with INNO-406, even in Bcr-Abl þ leukemias bearing imatinib-resistant Bcr-Abl point mutations. Notably, like Ph þ leukemias, most cancers maintain and propagate themselves by resisting apoptosis and enhancing cell proliferation.…”
mentioning
confidence: 79%
“…Although the mechanism has not been fully elucidated, Mcl-1 might have important role in the combination of INNO-406 and ABT-737. 19,34 This combination effect could be explained by the neutralization of Mcl-1 by Bim, which was not only induced by INNO-406 but also dissociated from Bim/Bcl-2 complex by ABT-737. 19,34 Indeed, the combination effect was largely abrogated in Mcl-1 highly expressing MYL-R (Supplementary Figure 3a, c).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…24 Mcl-1 expression has been found to be associated with resistance of cells to ABT-737. 25,26 Our results show that the Ku70-deficient MEF cells are more sensitive to ABT-737 than WT MEF cells (Figure 1c, right panel), indicating that downregulation of Mcl-1 by disruption of Ku70 can sensitize cells to Bcl2 inhibition.…”
Section: Resultsmentioning
confidence: 79%